LINC00511 interacts with EYA1 to promote the development of hepatocellular carcinoma via mediating miR‐195, which can be treated as a therapeutic biomarker for hepatocellular carcinoma diagnosis and treatment.12 Here, EYA1 is linked to hepatocellular carcinoma.